1887

Abstract

Dalbavancin was approved in Europe in 2015 for skin and soft tissue infections.

Data on methicillin-resistant coagulase-negative staphylococci (MR-CNS) dalbavancin susceptibility are scarce.

To assess the susceptibility of MR-CNS to dalbavancin and other anti-staphylococcal agents.

A total of 443 MR-CNS clinical isolates from patients hospitalized in a Greek university hospital during a 2.5-year period (January 2018 to June 2020) were included. The MICs for vancomycin, teicoplanin, linezolid and daptomycin were investigated by Etest and the MIC for dalbavancin was determined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines in 196 isolates. The consumption of the aforementioned antimicrobials was calculated.

In total, 51 isolates were resistant to teicoplanin (11.5 %) and 211 (47.6 %) to linezolid; all were susceptible to vancomycin and daptomycin. Among 196 isolates tested, 32 (16.3 %) were resistant to dalbavancin. A significant increase of MIC during the study period was found for vancomycin, teicoplanin and daptomycin, while a decrease in linezolid’s MIC was observed. Dalbavancin’s MIC remained stable. No difference in consumption was observed among the studied anti-staphylococcal agents.

An increase of vancomycin, teicoplanin and daptomycin MICs among MR-CNS was observed, whereas 47.6 % of isolates were non-susceptible to linezolid. Dalbavancin retains excellent potency against MR-CNS, even in the presence of non-susceptibility to other anti-staphylococcal antibiotics.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001419
2021-09-24
2021-10-24
Loading full text...

Full text loading...

References

  1. Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). Int J Antimicrob Agents 2018; 51:608–611 [View Article] [PubMed]
    [Google Scholar]
  2. Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B et al. French national cohort of first use of DALBAVANCIN: A high proportion of off-label use. Int J Antimicrob Agents 2019; 54:668–672 [View Article] [PubMed]
    [Google Scholar]
  3. Bouza E, Valerio M, Soriano A, Morata L, Carus EG et al. Dalbavancin in the treatment of different gram-positive infections: A real-life experience. Int J Antimicrob Agents 2018; 51:571–577 [View Article] [PubMed]
    [Google Scholar]
  4. Durante-Mangoni E, Gambardella M, Iula VD, De Stefano GF, Corrado MF et al. Current trends in the real-life use of DALBAVANCIN: Report of a study panel. Int J Antimicrob Agents 2020; 56:106107 [View Article] [PubMed]
    [Google Scholar]
  5. Rolston KVI, Wang W, Nesher L, Shelburne SA, Prince RA. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients. J Antibiot 2015; 69:381–387 [View Article]
    [Google Scholar]
  6. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 2009; 53:1260–1263 [View Article]
    [Google Scholar]
  7. Testing TECoAS Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0; 2020
  8. Petinaki E, Arvaniti A, Dimitracopoulos G, Spiliopoulou I. Detection of mecA, mecR1 and mecI genes among clinical isolates of methicillin-resistant staphylococci by combined polymerase chain reactions. J Antimicrob Chemother 2001; 47:297–304 [View Article] [PubMed]
    [Google Scholar]
  9. WHO Collaborating Centre for Drug Statistics Methodology Guidelines for ATC classification and DDD assignment, 2021. Oslo; 2020
  10. Papadimitriou-Olivgeris M, Giormezis N, Fligou F, Liakopoulos A, Marangos M et al. Factors influencing linezolid-nonsusceptible coagulase-negative staphylococci dissemination among patients in the intensive care unit: A retrospective cohort study. Chemotherapy 2013; 59:420–426 [View Article] [PubMed]
    [Google Scholar]
  11. Papadimitriou-Olivgeris M, Kolonitsiou F, Zerva L, Lebessi E, Koutsia C et al. Activity of vancomycin, linezolid, and daptomycin against staphylococci and enterococci isolated in 5 Greek hospitals during a 5-year period (2008-2012). Diagn Microbiol Infect Dis 2015; 83:386–388 [View Article] [PubMed]
    [Google Scholar]
  12. Žiemytė M, Rodríguez-Díaz JC, Ventero MP, Mira A, Ferrer MD. Effect of dalbavancin on Staphylococcal biofilms when administered alone or in combination with biofilm-detaching compounds. Front Microbiol 2020; 11:553 [View Article] [PubMed]
    [Google Scholar]
  13. Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis 2016; 36:677–680 [View Article]
    [Google Scholar]
  14. Fernández J, Greenwood-Quaintance KE, Patel R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis 2016; 85:449–451 [View Article] [PubMed]
    [Google Scholar]
  15. Sader HS, Carvalhaes CG, Streit JM, Arends SJR, Mendes RE. Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species. J Glob Antimicrob Resist 2021; 24:48–52 [View Article] [PubMed]
    [Google Scholar]
  16. Kolonitsiou F, Papadimitriou-Olivgeris M, Spiliopoulou A, Stamouli V, Papakostas V et al. Trends of bloodstream infections in a university greek hospital during a three-year period: Incidence of multidrug-resistant bacteria and seasonality in gram-negative predominance. Pol J Microbiol 2017; 66:171–180 [View Article] [PubMed]
    [Google Scholar]
  17. Katsarou I, Paraskevopoulou NM, Papadimitriou-Olivgeris M, Giormezis N, Militsopoulou M et al. Fatality of Staphylococcus aureus infections in a Greek university hospital: role of inappropriate empiric treatment, methicillin resistance, and toxin genes’ presence. Eur J Clin Microbiol Infect Dis 2019
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001419
Loading
/content/journal/jmm/10.1099/jmm.0.001419
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error